Totient enables next generation cell therapies and other therapeutic modalities by building the largest library of human-derived antibodies to novel and known tissue-specific antigens. The Totient engine uses machine learning, advanced immunoinformatics, and knowledge of the most recent research into tertiary lymphoid structures, in order to select and assemble the most potent monoclonal antibodies expressed in the tissue affected by autoimmunity, infections, and cancer.